MyFinsight

HomeBlogAboutContact

MyFinsight

Making company financials insightful for everyone

Quick Links

  • About
  • Blog
  • Contact

Follow Us

  • X.com
  • Thread
  • Instagram

© 2026 MyFinsight. All rights reserved.

|||

For the year ending 2025-12-31, RGNX had -$23,060K decrease in cash & cash equivalents over the period. -$126,377K in free cash flow.

Cash Flow Overview

Change in Cash
-$23,060K
Free Cash flow
-$126,377K
Unit: Thousand (K) dollars
Positive Cash Flow Breakdown
    • Maturities of marketable debt se...
    • Proceeds from issuance of royalt...
    • Stock-based compensation expense
    • Others
Negative Cash Flow Breakdown
    • Purchases of marketable debt sec...
    • Net loss
    • Repayments under royalty monetiz...
    • Others

Cash Flow
2025-12-31
Net loss
-193,878
Stock-based compensation expense
34,563
Depreciation and amortization
15,615
Net accretion of discounts on marketable debt securities
5,479
Net realized gain on investments
62
Non-cash interest expense
12,901
Other non-cash adjustments
-597
Accounts receivable
7,661
Prepaid expenses
2,860
Other current assets
-658
Operating lease right-of-use assets
-6,653
Other assets
613
Accounts payable
-2,284
Accrued expenses and other current liabilities
229
Deferred revenue
29,280
Operating lease liabilities
-8,625
Other liabilities
-2,997
Net cash used in operating activities
-123,963
Purchases of marketable debt securities
332,630
Maturities of marketable debt securities
319,114
Sales of equity securities
62
Purchases of property and equipment
2,414
Net cash provided by (used in) investing activities
-15,868
Proceeds from exercise of stock options
318
Taxes paid related to net settlement of stock-based awards
633
Proceeds from issuance of common stock under employee stock purchase plan
1,048
Expenses related to at-the-market offering programs
357
Proceeds from issuance of royalty bond and warrants, net of transaction costs
144,493
Repayments under royalty monetization liabilities, net of interest
28,098
Net cash provided by financing activities
116,771
Net increase (decrease) in cash and cash equivalents and restricted cash
-23,060
Beginning of period
59,556
End of period
36,496
Unit: Thousand (K) dollars (except for numbers of shares and EPS).

Time Plot

Show the time plot by selecting a row from the table.

Cash Flow

Proceeds from issuance ofroyalty bond and...$144,493K Proceeds from issuance ofcommon stock under...$1,048K Proceeds from exercise ofstock options$318K Net cash provided byfinancing activities$116,771K Canceled cashflow$29,088K Net increase(decrease) in cash and cash...-$23,060K Canceled cashflow$116,771K Stock-based compensationexpense$34,563K Deferred revenue$29,280K Depreciation andamortization$15,615K Non-cash interestexpense$12,901K Operating leaseright-of-use assets-$6,653K Other current assets-$658K Other non-cashadjustments-$597K Accrued expenses andother current...$229K Maturities of marketabledebt securities$319,114K Sales of equitysecurities$62K Repayments under royaltymonetization liabilities,...$28,098K Taxes paid related tonet settlement of...$633K Expenses related toat-the-market offering...$357K Net cash used inoperating activities-$123,963K Canceled cashflow$100,496K Net cash provided by(used in) investing...-$15,868K Canceled cashflow$319,176K Net loss-$193,878K Operating leaseliabilities-$8,625K Accounts receivable$7,661K Net accretion ofdiscounts on marketable...$5,479K Other liabilities-$2,997K Prepaid expenses$2,860K Accounts payable-$2,284K Other assets$613K Net realized gain oninvestments$62K Purchases of marketabledebt securities$332,630K Purchases of property andequipment$2,414K

REGENXBIO Inc. (RGNX)

REGENXBIO Inc. (RGNX)